Should screening for DPD deficiency be mandatory before 5-FU exposure?

Onkologie

Volumn 27, Issue 6, 2004, Pages 531-533

  McLeod, Howard ^a,b   Lim, Wan Teck ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GEFITINIB; THYMIDYLATE SYNTHASE;

ALOPECIA; BONE MARROW SUPPRESSION; BRAIN DISEASE; BREATH ANALYSIS; DIARRHEA; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DNA POLYMORPHISM; DNA SYNTHESIS INHIBITION; EDITORIAL; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME INHIBITION; GENE MUTATION; GENETIC ASSOCIATION; HEART MUSCLE ISCHEMIA; HEPATITIS; HUMAN; MUCOSA INFLAMMATION; NEUTROPENIA; NONHUMAN; RASH; STOMATITIS;

ANTINEOPLASTIC AGENTS; DIHYDROURACIL DEHYDROGENASE (NADP); FLUOROURACIL; HUMANS; MASS SCREENING; METABOLIC DISEASES; MULTIPLE ORGAN FAILURE; NEOPLASMS; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 10844252932     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000082641     Document Type: Editorial

References (24)

1. Santi DV, McHenry CS, Sommer H: Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate: Biochemistry 1974;13:471-481.
2. Mandel HG: The incorporation of 5-FU into RNA and its molecular consequences. Prog Mol Subcell Biol 1969;1:82-135.
3. Milano G, McLeod HL: Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment? Eur J Cancer 2000;36:37-42.
4. Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P: Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 1996;98:610-615.
5. Harris BE, Carpenter JT, Diasio RB: Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer 1991;68:499-501.
6. Sludden J, Hardy SC, VandenBranden MR, Wrighton SA, McLeod HL: Liver dihydropyrimidine dehydrogenase activity in human, cynomolgus monkey, rhesus monkey, dog, rat and mouse. Pharmacology 1998;56:276-280.
7. Van Kuilenburg AB: Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004;40:939-950.
8. Akay S, Ozutemiz O, Doganavsargil B: Severe colitis after administration of UFT chemotherapy for temporal bone carcinoma. Expert Opin Drug Saf 2004;3:89-92.
9. Ridge SA, Sludden J, Brown O, Robertson L, Wei X, Sapone A, Fernandez-Salguero PM, Gonzalez FJ, Vreken P, van Kuilenburg AB, van Gennip AH, McLeod HL: Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br J Clin Pharmacol 1998;46:151-156.
10. Meinsma R, Fernandez-Salguero P, Van Kuilenburg AB, Van Gennip AH, Gonzalez FJ: Human polymorphism in drug metabolism: Mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. DNA Cell Biol 1995;14:1-6.
11. Lu Z, Zhang R, Diasio RB: Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Clin Pharmacol Ther 1995;58:512-522.
12. Chazal M, Etienne MC, Renee N, Bourgeon A, Richelme H, Milano G: Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver. Clin Cancer Res 1996;2:507-510.
13. Fleming RA, Milano GA, Gaspard MH, Bargnoux PJ, Thyss A, Plagne R, Renee N, Schneider M, Demard F: Dihydropyrimidine dehydrogenase activity in cancer patients. Eur J Cancer 1993;29A:740-744.
14. Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N, Schneider M, Demard F, Milano G: Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994;12:2248-2253.
15. Di Paolo A, Danesi R, Falcone A, Cionini L, Vannozzi F, Masi G, Allegrini G, Mini E, Bocci G, Conte PF, Del Tacca M: Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol 2001;12:1301-1306.
16. Harris BE, Song R, Soong SJ, Diasio RB: Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990;50:197-201.
17. Raida M, Schwabe W, Hausler P, Van Kuilenburg AB, Van Gennip AH, Behnke D, Hoffken K: Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 2001;7:2832-2839.
18. Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH: Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: High prevalence of the IVS14+1g>a mutation. Int J Cancer 2002;101:253-258.
19. Collie-Duguid ES, Etienne MC, Milano G, McLeod HL: Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 2000;10:217-223.
20. Kouwaki M, Hamajima N, Sumi S, Nonaka M, Sasaki M, Dobashi K, Kidouchi K, Togari H, Wada Y: Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity. Clin Cancer Res 1998;4:2999-3004.
21. van Kuilenburg AB, Meinsma R, Zonnenberg BA, Zoetekouw L, Baas F, Matsuda K, Tamaki M, van Gennip AH: Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin Cancer Res 2003;9:4363-4367.
22. Lazar A, Mau-Holzmann UA, Kolb H, Reichenmiller HE, Rieß O, Schömig E: Multiple organ failure due to 5-fluorouracil chemotherapy in a patient with a rare dihydropyrimidine dehydrogenase gene variant. Onkologie 2004;27:559-562.
23. Gross E, Ullrich T, Seck K, Mueller V, de Wit M, von Schilling C, Meindl A, Schmitt M, Kiechle M: Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects. Hum Mutat 2003;22:498.
24. Mattison LK, Ezzeldin H, Carpenter M, Modak A, Johnson MR, Diasio RB: Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin Cancer Res 2004;10:2652-2658.